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ABSTRACT
Sudden Unexpected Death in Epilepsy [SUDEP] is one of the major causes of death within
the world population that has epilepsy (Partemi, et al., 2014). There is no clear consensus on the
underlying mechanism and are theorized to be heterogeneous in nature (Nashef et al., 2012).
Some of these mechanisms are cardiac arrhythmias, and dysfunctions in either the respiratory or
brainstem arousal systems (Ruthirago et al., 2018).

Postmortem testing could provide further

understanding of SUDEP and could be used as an asset to medical examiners. In this study we
seek to evaluate the utility of postmortem genetic testing as part of a pilot study utilizing
in-house postmortem molecular analysis at NYC-OCME on SUDEP cases retrospectively and
prospectively.

Thirty-two cases were analyzed by In-house Cardiac & Epilepsy Sudden Death

Molecular Analysis. Among the 19 definite or definite SUDEP plus cases, two likely pathogenic
variants have been identified in two definite SUDEP cases. Testing yield, percentage of cases
with positive results is calculated to be 10.5%. 17 of the 19 definite or definite SUDEP cases
(89.5%, one case has both a likely pathogenic variant and a variant of uncertain significance
[VUS] identified) have one or more VUS identified. One case (5.3%) has a negative result with
no variants identified in the 257 genes tested. A likely pathogenic splice-site missense variant
was found in SCN2A in a 9 year-old female with White/Caucasian ethnicity. A likely pathogenic
frameshift variant was found in CACNA1H in a 27 year-old male with Hispanic ethnicity. Our
results show the utility of postmortem molecular testing in SUDEP. Accurate variant
interpretation and classification as well as risk assessment is essential for patients and families
affected by SUDEP. More research and data collection on variants discovered through NGS in
varied racial/ethnic populations is required.
Key words: Sudden Unexpected Death in Epilepsy, SUDEP, epilepsy, sudden death, postmortem
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INTRODUCTION
Epilepsy affects 3% of the world population. In this specific group affected by this
condition, Sudden Unexpected Death in Epilepsy [SUDEP] is one of the major causes of death.
Compared to the rest of the population, the rate of sudden death is 24 times higher in individuals
with epilepsy (Partemi, et al., 2014). The incidence of SUDEP has been reported as 1.4/1,000
patients-years (CI 0.9/1,000-2.2/1,000) (Saetre & Abdelnoor, 2018) and 41.1/100,000
person-years (CI 31.6-54.9) (Holst et al., 2013). It occurs more frequently in adults with epilepsy
than in children (Saetre & Abdelnoor, 2018; Harden, et al., 2017). Harden, et al. in 2017
mentioned that it occurs in 1 out of 4,500 children with epilepsy per year, while in adults with
epilepsy it occurs in 1 out of 1,000 per year. Although cases are more common in 21-50 year-old
patients (Ruthirago, Julayanont, Karukote, Shehabeldin, & Nugent, 2018), patients at any age are
at risk. As such, it is important to expand our understanding of this circumstance.
Since 1868, there has been a need to classify death associated with epilepsy (Nashef, 1997).
It was in 1997 when Nashef established it was essential to reach a consensus in classification of
deaths due to epilepsy such as SUDEP to be able to improve research and statistics in this area.
At the time he defined SUDEP as death in patients known to have epilepsy that, as the name
indicates, was both sudden and unexpected, not associated with trauma or drowning, could have
been either witnessed or unwitnessed, with or without evidence of a seizure, where no other
cause of death was determined after an autopsy.
In the same volume of Epilepsia in 1997, J. F. Annegers sought to explore previous SUDEP
terminology and classification. It includes the Food and Drug Administration [FDA] and
Burroughs SUDEP criteria from 1993 that was used to evaluate SUDEP cases in clinical trials.
The author states the criteria did look to exclude accidental deaths as SUDEP but didn’t
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specifically prevent certain situations from being considered. Depending on how each case
fulfilled the criteria it was classified as “definite SUDEP, probable SUDEP, possible SUDEP,
unlikely or nor SUDEP”. It mentions how in general the term SUDEP could be either used when
little or poor documentation is available in a death related to SUDEP or when the evidence is
enough but there seems to be other conflicting explanations of the death.
The definition and classification for SUDEP that is frequently and currently used in
research was proposed in “Unifying the definitions of sudden unexpected death in epilepsy”
(Nashef, So, Ryvlin, & Tomson, 2012). The definition for definite SUDEP is similar to Nashef’s
definition and excluded deaths that were preceded by status epilepticus. It introduces the term
SUDEP Plus when a concomitant condition is present but not determined to be the ultimate
cause of death. If no autopsy has been performed but otherwise could be defined as SUDEP, it is
classified as Probable SUDEP. When there is another possible cause of death it is defined as
Possible SUDEP. Further classification includes Near-SUDEP, Not SUDEP, and Unclassified.
These are used when a case meeting the definition is resuscitated, another cause of death is
determined, and when it's not possible to classify the death. The authors looked to unify and
reexamine the most commonly used definitions of SUDEP in research, to reduce ambiguity
while at the same time allowing cases which would formerly be excluded as SUDEP to be
investigated. Their aim was to create a classification that would allow researchers to apply the
different SUDEP categories in a way that is particular to each specific area of their studies. This
allows an opportunity to expand knowledge on SUDEP risk factors and mechanisms.
Risk factors for SUDEP include generalized tonic-clonic seizures [GTCS], frequent GTCS,
not being seizure free for 1-5 years, and not modifying patient medication in uncontrolled
epilepsy cases. If the epilepsy is drug-resistant, the lifetime cumulative risk can be as high as
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35% (Chahal et al., 2020). Supervising epilepsy patients during the night and use of night
listening devices are considered moderate risk reduction factors. (Coll et al.,2019; Harden, et al.,
2017)
The mechanisms theorized to be involved in SUDEP are diverse and research studies on this
topic are complicated due to small amounts of autopsies performed, low incidence,

and since it

usually occurs unpredictably and without a witness (Nashef et al., 2012). Although plenty of
research has tried to identify the mechanisms of SUDEP, there is not a specific consensus.
Ruthirago, et al. (2018) state that current evidence suggests that some plausible mechanisms are
cardiac arrhythmias or dysfunctions in either the respiratory or brainstem arousal systems.
Animal models study and seem to support the role of neurotransmitters in these deaths. In their
review, they mention that investigators consider that SUDEP is caused by a combination of
factors and processes that in conjunction lead to a fatal outcome. Coll, et al. (2019) refers that
one of the studies reviewed suggested that after a GTCS, both respiratory and cardiac systems
are comprised leading to a “postictal neurovegetative breakdown.”
Several reviews and studies (Devinsky, 2011; Partemi, et al., 2014; Ruthirago, et al., 2018;
Coll, et al., 2019) mention that cardiac factors play a role in the mechanism of SUDEP. Seizures
cause cardiac dysfunction in the form of arrhythmias; this may include sinus tachycardia,
supraventricular or ventricular tachycardia, bradycardia, and asystole (Ruthirago, et al., 2018).
Devinsky (2011) mention that other cardiovascular changes in ictal and interictal periods include
QT interval prolongation as well as shortening of the QT interval postictally.
In 1996, Nashef, Walker, Allen, Sander, Shorvon, & Fish, concluded that the association of
apnea and bradycardia showed that the cardio respiratory reflexes could play a part in SUDEP. In
the review by Devinsky, 2011, the author makes reference to impaired respiration being
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witnessed during SUDEP. Hypoxemia itself can also cause cardiac complications (Ruthirago, et
al., 2018).
Another mechanism thought to be involved in SUDEP is the arousal and consciousness
center. This center located in the brainstem, when affected by seizures, could lead to airway
obstruction or aspiration. Autonomic functions as well as cardiovascular and respiratory systems
also depend on neurons located in the brainstem. (Ruthirago, et al., 2018)
New studies have shown that there could be certain genetic markers that increase SUDEP
risk. To be considered as a gene associated with SUDEP, the genetic alteration should cause
epilepsy and affect the nervous system and/or alter respiratory, cardiac or autonomic functions.
(Ruthirago, et al., 2018; Coll, et al., 2019) The genes being studied include those involved in ion
channel function and certain encephalopathies that also target heart tissue.

(Coll, et al., 2019)

There have been a small number of studies that performed genetic analysis on SUDEP
cases. The genetic panels utilized in these studies targeted genes associated with Long QT
Syndrome [LQTS], cardiac channelopathies, arrhythmia, central hypoventilation, and epilepsy.
Studies reported rare, de novo, pathogenic, candidate pathogenic, and likely pathogenic variants.
Genes where variants were found are: KCNH2, SCN5A, KCNQ1, KCNE2, RYR2, ANK2, AKAP9,
SCN1B, KCNE1, SCN10A, HCN4, DEPDC5, GABRB3, PAFAH1B1, SCN1A, SCN2A, CHRNA4,
KCNQ2, PCDH19, SCN1B, SPTAN1, EFHC1, HCN1, KCNQ3, CACNA1A, FBN1, SCN4A, and
SCN11A (Bagnall et al., 2016; Coll et al., 2015; Coll et al., 2017; Partemi et al., 2014; Tu et al.,
2011).
Recently, Chahal et al. (2020), published a systematic review of 8 studies that analyzed the
genetics of SUDEP. The genes identified to have a possible association to SUDEP included
KCNH2, SCN5A, KCNQ1, SCN1A, LGI1, PIK3C2A, SMC4, COL6A3, TIE1, DSC2, LDB3,
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KCNE1, MYBPC3, MYH6, DSP, DSG2, and DMD; four different duplications involving
chromosome 15 were also found. Most variants were classified as variants of uncertain
significance [VUS]. Of the few that were classified as pathogenic or likely pathogenic [P/LP] at
postmortem, most are related to sodium and potassium channels, with an approximate 11%
discovery rate.
In literature, studies look to find an underlying genetic cause to SUDEP.

Cohort studies

vary from postmortem SUDEP cases to live patients with epilepsy with personal or family
history of issues with cardiac conduction and SUDEP (Chahal et al., 2020). In the literature that
was reviewed, two studies (Bagnall et al., 2016; Tu et al., 2011) analyzed only post-mortem
cases. The other studies reviewed the latter category (Coll et al., 2015; Coll et al., 2017; Partemi
et al., 2014). Some seeked to find possible associations between epilepsy and channelopathies
(Partemi et al., 2014). There is a bigger number of studies whose

gene panels focus

predominantly on cardiac disease. Overall there is a lack of studies that focus on postmortem
genetic testing in SUDEP cases.
Due to the small number of publications and the small size of cohorts, it is not possible to
find a meta-analysis report. In the latest review by Chahal et al. (2020), they selected 8 articles
with 161 unique individuals. The small amount of data that could be collected was not enough
to perform a meta-analysis report. Other cohorts had the same issue (Bagnall et al., 2016; Coll et
al., 2015; Coll et al., 2017; Partemi et al., 2014; Tu et al., 2011).
In 2019, the New York City Office of Chief Medical Examiner [NYC-OCME] conducted
an in-house study to evaluate the efficacy of post mortem genetic testing in a sudden cardiac
death cohort and its impact on determining cause of death. A panel of 95 genes associated with
cardiac channelopathy and cardiomyopathy were evaluated. The positive yield was 10.6%; in
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39% of decedents, a VUS was found. This

study was a part of the NYC-OCME incursion into

postmortem genetic testing for sudden death (Williams et al., 2019). They have now incorporated
into their in-house postmortem panel epilepsy genes. This study utilizes their patient database
and testing methodology.
The purpose of post mortem genetic testing is to try and elucidate the cause of death when
none can be established after a traditional autopsy, through molecular study. The aim of this
study is to evaluate the role of post mortem genetic testing for cases of SUDEP as part of a pilot
study for real-time, prospective cases within the NYC-OCME utilizing in-house expanded panel.

MATERIALS AND METHODS
For this study, we incorporated the methodology and procedures used by Williams et al.
(2019) in “Lessons learned from testing cardiac channelopathy and cardiomyopathy genes in
individuals who died suddenly: A two-year prospective study in a large medical examiner’s
office with an in-house molecular genetics laboratory and genetic counseling services” since it
was performed in the same setting, utilizing the same procedures and patient database.
Participants
We reviewed thirty-two suspected SUDEP cases investigated for sudden death by the
NYC-OCME from 2016 to 2019 with postmortem genetic testing done through an in-house
customized multigene Cardiac and Epilepsy Sudden Death Molecular Analysis panel at the
NYC-OCME. Information on age, race/ethnicity, biological sex, postmortem genetic testing
results, anatomical and heart findings, toxicology, circumstances of death (i.e. witnessed or un
witnessed, body position, etc.), and personal medical history were collected from the
NYC-OCME internal records system on the cases tested. Such records included scene
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investigation by police, family interviews, complete gross autopsy, neurologic and cardiac
pathology examinations, toxicological records, as well as genetic reports and medical or hospital
records where available. For the purposes of this study, race and ethnicity are grouped together
and determined by the family report at the time of identification. Utilizing Nashef et al. (2012)
proposed unified SUDEP classification and the information collected from NYC-OCME, the
cases were further classified into Definite SUDEP, Definite SUDEP Plus, Probable
SUDEP/Probable SUDEP Plus, Possible SUDEP, Near-SUDEP/Near-SUDEP Plus, Not SUDEP,
and Unclassified. The cases having accidents involved in the manner of death don't fall into the
aforementioned classifications and are listed seperately.
Instrumentation and Procedures
Next generation sequencing (NGS) was used to analyze 257 genes associated with
cardiomyopathy, channelopathy, and epilepsy-related disorders. A full list of genes and
associated disorders is in Supplemental Table S1. The Molecular Genetics Laboratory at
NYC-OCME, CAP accredited, developed this expanded genetic panel. The test was performed
on genomic DNA from dry blood spot cards or postmortem tissue samples collected at the time
of autopsy and preserved in a nucleic acid stabilizing solution (RNAlater®). The analysis
performed includes sequencing the regions of interest for each gene tested that included the
coding regions and ± 10 bp introns flanking exon/intron junctions. Oligonucleotide based
in-solution target capture (Agilent Technologies) was performed, followed by NGS. Illumina
NextSeq 500 Local Run Manager was used to perform primary sequencing data analysis to
generate a sequencing read. Secondary sequencing was then performed using NextGENe
(SOFTGENETICS) and included the delivery of alignment data, variant identification, and
filtering the sequence by quality. Geneticist Assistant (SOFTGENETICS®) was used for variant
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classification. Sanger sequencing was used to confirm low confidence reportable variants (the
coverage is below 100x, allele frequency is less than 25%, and reads balance is less than 0.25) or
to provide sequencing data for clinically significant regions of a gene that has no NGS data
coverage.

Sanger

sequencing

data

analysis

is

performed

in

Mutation

Surveyor

(SOFTGENETICS®). For single nucleotide variants (SNVs) and insertions and deletions
(in/dels) variants shorter than 20 bp, the analytical sensitivity is 99.46% (95% CI [98.04%,
100%]) and the analytical specificity is 100% (95% CI [99.9996%, 100%]) determined through
in-house validation studies.
Reported variants were evaluated using the

Guidelines by the American College of

Medical Genetics and Genomics and the Association for Medical Pathology (Richards et al.,
2015). The variant interpretation was executed within the NYC-OCME molecular genetics lab
by a geneticist. After, the director of the laboratory and the genetic counselor further reviewed
the interpretation. Only variants classified as pathogenic, likely pathogenic, or VUS were
reported. The Human Genome Variant Society was used to establish variant nomenclature and
the genomic reference coordinate used was GRCh37/hg19.
Data Analysis
Descriptive statistics were utilized to calculate testing yield, or percentage of cases with
positive results. The testing yield rate is calculated by excluding VUS variants submitted
previously to ClinVar as P/LP.
Ethical compliance
This research was approved by the Chief Medical Examiner and by the general counsel at
the NYC-OCME and the Institutional Review Board at Sarah Lawrence College deemed the
study exempt and waved informed consent.
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RESULTS
SUDEP Case Classification
Of the 32 prospective SUD cases with a history of seizures, 19 were categorized as definite
SUDEP or definite SUDEP plus cases: definite (n=17) and definite plus (n=2).

Thirteen cases

were excluded due to having cause of death determined other than SUDEP (n=5), no autopsy
(n=2), accident involved in manner of death (n=4), and undetermined cause of death (n=2).
Demographic Information
The overall demographics of the 19 definite/definite plus SUDEP cases in (Table 1): 11
females (1 transgender female) and 8 males; 12 Blacks/African American descendants (63.2%),
4 Hispanics (21.1%), and 3 Whites/Caucasian descendants (15.8%); 2 children (1 year to 17
years), 12 young adults (18 to 34 years), and 5 adults (35 to 55 years).
Table 1. Demographics of 19 Definite/Definite Plus Sudden Unexpected Death in Epilepsy
Cases
Ethnicity

Age Cases, n (%)
Children (1– Young
17 y)
Adults
(18–34 y)
Black
1 (8.3)
9 (75)
Hispanic
0 (0.0)
2 (50)
White
1 (33.3)
1 (33.3)
Total
2 (10.5)
12 (63.2)
*1 transgender female

Adults
(35–55 y)
2 (16.7)
2 (50)
1 (33.3)
5 (26.3)

Sex Cases, n (%)
Female
Male

Subtotal
Cases, n (%)

7 (58.3)
2* (50)
2 (66.7)
11 (57.9)

12 (63.2)
4 (21.1)
3 (15.8)
19 (100.0)

5 (41.7)
2 (50)
1 (33.3)
8 (42.1)

Molecular Analysis Results
Among the 19 definite or definite SUDEP plus cases, two likely pathogenic variants have
been identified in two definite SUDEP cases. Testing yield, percentage of cases with positive
results is calculated to be 10.5%. 17 of the 19 definite or definite SUDEP cases (89.5%, one case
has both a likely pathogenic variant and a VUS identified) have one or more VUS identified.
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One case (5.3%) has a negative result with no variants identified. The distribution of P/LP and
VUS results in different genes is shown in Figure 1. Variants were identified in 29 of the total
257 genes analyzed. Genes with P/LP variants were SCN2A and CACNA1H. Genes that had
more than 1 VUS detected were AKAP9, ANK2, FLNA, GLI2 and SCN9A.

Figure 1. Results of In-house Cardiac & Epilepsy Sudden Death Molecular Analysis in 19
Definite/Definite Plus SUDEP Cases. No uncertain, likely pathogenic, or pathogenic variants
were detected in the remaining 228 genes assessed through the panel and are not included in this
figure.
The distribution of the P/LP and VUS found in both definite/definite plus SUDEP and
non-definite/definite plus SUDEP cases by age group is shown in Figure 2. Among the nineteen
definite/definite plus SUDEP cases, one P/LP variant was found in children (50%); one P/LP
variants was found in young adults (8.3%); and no P/LP variants were found in adults. One
definite/definite plus SUDEP case has both a P/LP variant and a co-existing VUS found (Table
2). The proportion of cases with VUS and other co-existing VUS were analyzed by age group
revealing a small proportion of cases in each age group had more than one VUS (Table 2).
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Approximately 37% of cases in all age groups had novel variants (Table 2). All thirteen
non-definite/definite plus SUDEP cases have one or more VUS but no P/LP variants found
(Table 3). Approximately 19% of cases in all age groups had novel variants (Table 3).

Figure 2. Distribution of P/LP And VUS in 32 Cases Analyzed by In-house Cardiac & Epilepsy
Sudden Death Molecular Analysis by Age Group. P/LP: pathogenic/likely pathogenic; VUS:
variant of uncertain significance; YA: young adult
Table 2. Distribution of P/LP and VUS by Age Group in Definite/Definite Plus SUDEP Cases
Variants
P/L+0VUS
P/LP+1VUS
Total P/LP
VUS+0VUS
VUS+1VUS
VUS+2VUS
VUS+3VUS
VUS+5VUS
Total VUS
Novel VUS

Children
0
1
1
0
1
0
0
0
2 (6.7)
1 (50.0) (9.1)

Young Adults
1
0
1
5
2
2
0
1
21 (70.0)
9 (42.9) (81.8)

Adults
0
0
0
3
0
0
1
0
7 (23.3)
1 (14.3) (9.1)

Total
1
1
2
8
3
2
1
1
30
11 (36.7)
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Table 3. Distribution of VUS by Age Group in Non-Definite/Definite Plus SUDEP Cases
Variants
VUS+0VUS
VUS+1VUS
VUS+2VUS
VUS+4VUS
Total VUS
Novel VUS

Children
0
3
2
1
17 (53.1)
2 (11.8) (33.3)

Young Adults
4
1
1
1
14 (43.8)
4 (28.6) (66.7)

Adults
1
0
0
0
1 (3.1)
0 (0.0) (0.0)

Total
5
3
3
2
32
6 (18.75)

Genes with Likely pathogenic variants Identified in This Study
In-house Cardiac & Epilepsy Sudden Death Molecular Analysis identified 2 novel likely
pathogenic variants in this 19 cases cohort, as shown in Table 4. A likely pathogenic splice-site
missense variant was found in SCN2A (sodium channel, voltage-gated, type II, alpha subunit;
benign familial infantile seizures and early infantile epileptic encephalopathy 11; OMIM:
182390) in a 9 year-old female with White/Caucasian ethnicity. Review of decedent’s forensic
examination revealed history of seizure disorder with unknown etiology. Decedent’s last seizure
was reported to be the night before death in the medical record gathered by NYC-OCME.
Decedent was reported to be compliant with anti-epileptic medication. Neuropathology
examination revealed reactive astrocytes and microglial nodules in CA4 of bilateral hippocampi
with focal slight perivascular and leptomeningeal mononuclear inflammation, which reflected
history of seizure disorder and recent seizure. Cardiac pathology examination and autopsy
revealed a normal heart.
A likely pathogenic frameshift variant was found in CACNA1H (calcium channel,
voltage-dependent, T Type, alpha 1 H subunit; disorders include tonic–clonic and febrile
seizures; OMIM: 607904) in a 27 year-old male with Hispanic ethnicity. Review of decedent’s
forensic examination revealed 2 years of seizure with unknown etiology. Neuropathology
examination, cardiac pathology examination and autopsy were unremarkable.
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Table 4. List of Definite/Definite Plus SUDEP Cases with P/LP
Age, y Sex Ethnicity PHx* SUDEP Gene
Variant
Comments
9
F
White
Yes Definite SCN2A
Splice-site, missense Likely Pathogenic
27
M Hispanic Yes Definite CACNA1H frameshift
Likely Pathogenic
*PHx: Previous history of seizure
Genes with VUS Identified in This Study
Among the nineteen definite/definite plus SUDEP cases in this study, seventeen cases have
one or more VUS identified by the in-house Cardiac & Epilepsy Sudden Death Molecular
Analysis. Thirty-four VUS were identified in 27 genes including AKAP9, ANK2, CACNA1A,
CACNB2, CASK, CDKL5, CHD2, CTNNA3, DES, DSC2, DYRK1A, FHOD3, FLNA, FLNC,
GFAP, GLI2, HCN1, KCNK3, KMT2D, MYPN, NSD1, RBM20, RYR2, SCN9A, SLC25A22,
TRPM4 and TSC2, among which eleven VUS found in AKAP9, ANK2, CACNA1A, CDKL5,
CHD2, CTNNA3, FLNA, GLI2, KMT2D, SCN9A, are considered as novel VUS based on the lack
of records in HGMD (Table 5).
Table 5. List of Definite/Definite Plus SUDEP Cases with VUS
Case
No.
1
2

Age,
y
9
14

Sex Ethnicity PHx* SUDEP Gene

Variant Type

F
M

White
Black

Yes
Yes

Definite AKAP9
Definite ANK2, CDKL5

3
4

26
26

F
M

Black
Black

Yes
Yes

Definite SCN9A, AKAP9
Definite SCN9A, CHD2

5

26

F

Black

Yes

CASK

6
7
8
9

28
28
30
31

M
M
F
M

Black
Black
Black
Hispanic

Yes
Yes
Yes
Yes

Definite
Plus
Definite
Definite
Definite
Definite

VUS
ANK2 VUS (RARE); novel
CDKL5 VUS
Novel AKAP9 VUS
Novel CHD2 VUS; novel
SCN9A VUS;
VUS

10

31

F

Black

Yes

ANK2
KMT2D
SLC25A22
CACNA1A,
MYPN, TSC2
Definite CTNNA3, GLI2,
KCNK3, NSD1,
RBM20, TRPM4

Novel VUS
Novel VUS
VUS
Novel CACNA1A VUS;
MYPN VUS; TSC2 VUS
Novel CTNNA3 VUS;
novel GLI2 VUS; KCNK3
VUS; NSD1 VUS; RBM20

14

VUS; TRPM4 VUS
FLNA
Novel VUS
ANK2, DYRK1A, VUS
RYR2
FLNA, FLNC,
VUS
HCN1
DES
VUS

11
12

33
34

F
F

Black
Black

Yes
Yes

Definite
Definite

13

35

F

Hispanic

Yes

Definite

14

36

F

Black

Yes

15

37

M

Black

Yes

Definite
Plus
Definite CACNB2,
FHOD3, GFAP,
GLI2
Definite FLNA
Definite DSC2

16
44
F
White
Yes
17
46
M Hispanic Yes
*PHx: Previous history of seizure

VUS
Novel VUS
VUS

Genetic Findings in Non-Definite SUDEP/Definite SUDEP Plus Cases
In-house Cardiac & Epilepsy Sudden Death Molecular Analysis was performed in cases not
classified as definite/definite plus SUDEP cases based on the Nashef’s SUDEP definition. All
cases were found to have one or more VUS, but no P/LP variants. (Table 6) One or more VUS
have been identified in the 5 cases with cause of death other than SUDEP determined by the
medical examiner. Thirteen VUS were identified in 12 genes including CACNA1A, CACNA1E,
CACNA1H, CHRNB2, GNB5, HCN1, NEBL, PKP2, PRKAG2, SCN8A,

TJP1, TNNI3K. There

were 3 VUS identified in the two cases with no autopsy records but medical history of seizure
disorder (one case with unknown medical history). One case has a VUS in the gene GLA and the
other case has two VUS in the genes LAMA4 and GRIN2B. In the four cases having accident
involved in the manner of death, one or more VUS have been identified in 10 genes including
ABCC8, ANK2, CACNA1A, CDH2, CDKL5, DSP, KCNJ11, LGI1, NSD1, RYR2. Lastly, in the
two cases with undetermined cause of death, there was one VUS identified in the gene SCN4A in
one case and three VUS in the genes KMT2D, SLC6A8, SYNGAP1 in the other case.
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Table 6. List of Non-Definite/Definite Plus SUDEP Cases
Case Age,
No. y
1
4

Sex Ethnicity PHx* SUDEP
M

Black

2
3

11
13

M
M

Hispanic Yes
Hispanic Yes

4

28

F

Hispanic Yes

5

34

M

Asian

Yes

6

11

M

Black

Yes

7

19

M

Black

No

8

19

F

Black

Yes

9

27

F

White

Yes

10

29

F

Black

Yes

11

39

M

White

Yes

12

1

M

White

Yes

Yes

13
26
F
White
No
*PHx: Previous history of seizure

Gene

Not SUDEP CACNA1A, GNB5,
NEBL, PKP2,
PRKAG2
Not SUDEP CHRNB2, PKP2
Not SUDEP HCN1, TJP1,
TNNI3K
Not SUDEP CACNA1H
Not SUDEP CACNA1E,
SCN8A
Probable (no GRIN2B, LAMA4
autopsy)
Probable (no GLA
autopsy)
Accident
CDKL5
involved
Accident
ANK2, CDH2,
involved
RYR2
Accident
ABCC8,
involved
CACNA1A, DSP,
LGI1, NSD1
Accident
KCNJ11
involved
Unclassified KMT2D, SLC6A8,
SYNGAP1
Unclassified SCN4A

Variant Type
VUS
PKP2 VUS (RARE)
VUS
Novel CACNA1H
VUS
Novel CACNA1E
VUS
Novel GRIN2B VUS
VUS
VUS
ANK2 VUS (RARE)
Novel ABCC8 VUS;
novel LGI1 VUS
VUS
Novel SYNGAP1 VUS
VUS

DISCUSSION
When we reviewed the cases, only four had SUDEP as the cause of death. In other cases,
the causes of death were determined as associated with epilepsy. Establishing SUDEP as a cause
of death is a challenge since it is an exclusion diagnosis, and in suspected cases an autopsy
should be performed to exclude other competing causes of death (Thom, 2007).

After further
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analysis of the cases, we classified 59% of the initial cases reviewed as definite SUDEP or
SUDEP plus. The full in-house postmortem examination performed at the NYC-OCME allowed
us to further define these cases. This reflects the importance of performing an autopsy on a
suspected SUDEP.
The demographic in our cohort, although small, was ethnically diverse with a predominance
for minority populations: 63.2% Black/African American descendant and 21.1% Hispanic. The
percentage of the Black/African American population in our cohort’s demographic is higher than
the reported 24.3% population in New York City, but the Hispanic population was similar to the
reported 29.1% (“United States Census Bureau”, 2018). Although the cohort was made up of
sudden death cases, previous post mortem studies performed by NYC-OCME have similar enthic
demographics (Lin et al., 2017; Williams et al., 2019). As Williams et al. (2019) mentioned “the
overrepresentation of the Black/African American population in our cohort may be due to an
intrinsic factor not identified” in this or previous studies in this setting. It has been previously
documented that there exists racial disparity to access to specialized care in epilepsy, specially in
the Black/African American and Hispanic populations (Nathan & Gutierrez, 2018; Schiltz et al.,
2013; Szaflarski et al., 2006). This could be the reason for the overrepresentation, but with the
data collected from this study, we can not specifically confirm this was an influencing factor.
The distribution of age in our cohort was similar as previously documented (Saetre &
Abdelnoor, 2018; Harden, et al., 2017) with more adult decedents than children, but the main
difference was that the quantity of people in each group varied widely: two cases age 18 or
younger and 17 cases age 18 or older. In this study, we did not find an intrinsic factor for this,
but the small sample size could be an explanation for this disparity.
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The two LP variants were found in SCN2A and CACNA1H. SCN2A encodes the sodium
channel, voltage-gated, type II, alpha subunit. Voltage-gated sodium channels are
transmembrane glycoprotein complexes composed of a large alpha subunit with four repeat
domains. Each alpha subunit is composed of six membrane-spanning segments, and one or more
regulatory beta subunits. The function of voltage-gated sodium channels is generating and
propagating action potentials in neurons and muscle. P/LP variants in SCN2A have been reported
to be associated with autism spectrum disorder, benign familial infantile seizures, early infantile
epileptic encephalopathy 11 and genetic epilepsy with febrile seizures plus (GEFS+). At least
three SUDEP with variants in SCN2A have been reported, including two with de novo mutations.
It remains to be determined why the early onset epileptic syndromes caused by variants in
voltage-gated sodium channels, SCN1A, SCN2A, and SCN8A should have a high risk of SUDEP,
but may be directly related to their effects on cardiorespiratory function, or their association with
known SUDEP risk factors, such as generalized tonic–clonic seizures, young age at seizure
onset, and intractable epilepsy (Bagnall et. al. 2017). CACNA1H encodes the calcium channel,
voltage-dependent, T type, alpha-1H subunit. Calcium channels are a group of protein complex
mediating the influx of calcium ions into the cell upon membrane polarization. The protein
complex are made of different subunits including alpha-1, alpha-2/delta, beta, and gamma
subunits in a 1:1:1:1 ratio. Each subunit has multiple isoforms either encoded by different genes
or resulted from alternative splicing of transcripts. CACNA1H is one of the alternate
transcriptional splice variants (NCBI Gene. 2020). P/LP variants in CACNA1H have been
reported to be associated with susceptibility to childhood absence epilepsy 6 and familial
hyperaldosteronism type IV. One potentially pathogenic variant in CACNA1H has been detected
in a SUDEP cohort study published in 2017 (Coll et.al. 2017).
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Testing yield of this study, percentage of cases with positive results (10.5%), is close to the
11% discovery rate described by previous cohort studies on genetic testing of SUDEP cases
(Chahal et al. 2020). With the small sample size, we have limited information to determine if the
consistency is an accurate reflection of testing yield of genetic testing of SUDEP cases.
Compared with cases with P/LP results, cases with VUS results make up the majority of the
nineteen SUDEP cases in our study. In the cases not classified as definite/definite plus SUDEP,
we detected a great number of VUS in a wide range of genes but no P/LP variants. The lack of
P/LP variants in the non-definite/definite plus SUDEP cases suggests the need to establish a
clearer clinical and post-mortem criteria to classify SUDEP cases to facilitate variant
interpretation by establishing better phenotype-genotype correlations in SUDEP. Among the
identified VUS in all 32 cases tested, there are a large number of novel and rare VUS (Table 2, 3,
5 and 6) that can not be reclassified as benign with the current published clinical and function
studies. The dominating result type of VUS in all cases emphasizes the importance of conducting
SUDEP studies with larger sample size and involving samples from SUDEP decedents with
diverse ethnic backgrounds to provide more clinical and function data for possible variant
interpretation and classification. More definitive variant interpretation and classification is the
premise of providing informative genetic counseling and targeted medical surveillance and
management recommendations for possibly affected patients and family members to reduce the
risk of SUDEP and eventually prevent SUDEP.
Of the 257 genes analyzed by the In-house Cardiac & Epilepsy Sudden Death Molecular
Analysis for this study, we found variants (LP/VUS) in 28 genes in the nineteen definite/definite
plus SUDEP cases tested (10.9%). The relatively high rate of genes with findings in a small
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cohort elucidates the well classified SUDEP cases and the well designed breadth of genes
included in the panel.

LIMITATIONS
One limitation in this study is that the information collected on the decedent's family and
personal history was based on family reporting collected from investigation, police reports and
medical records from hospitals. The police and investigation reports varied in the way the report
was presented as well as how detailed it was. There was not a consistency between reports and
therefore we could not establish if specific details in the personal history were lacking because
questions were not asked or not answered, or if each individual gave a different level of
importance to past medical history while completing their report. Investigators also had different
types of access to people who could provide more background information. For example there
were instances where a decedent’s physician had been contacted in other cases there was no
close relative or acquaintance that could provide more accurate information on the case. Medical
records may not always be acquired from hospitals due to the differences of circumstances of
death and decedents’ accessibility to healthcare when alive.
Due to the small sample size, the analysis of the corralation between the incidence of
SUDEP and sex, ethinicity, age and other demographic factors is limited. Testing yield from a
small study may not be able to accurately predict the testing yield in a larger sample.

CONCLUSIONS
This research further addresses the importance of performing molecular postmortem genetic
testing on SUDEP cases. This may help at‐risk families to find the underlying reason for the
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onset of SUDEP, which can not be revealed by standard autopsy with no molecular testing. The
in-house testing laboratory at the NYC‐OCME is where extensive genetic sequencing and
interpretation can take place to facilitate the incorporation of molecular postmortem testing into
standard autopsy. The LP variants and large amount of VUS revealed by this pilot study suggests
the need to test available SUDEP cases retrospectively and prospectively at the NYC-OCME and
other institutions to allow more research and data collection on variants discovered through NGS
in varied racial/ethnic populations. As more information is collected on variants in healthy
populations, affected individuals and their family members, VUS can be further classified and
better clarity can be achieved.
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APPENDIX
Supplemental Table S1. List of Genes in the NYC-OCME In-house Cardiac & Epilepsy Sudden
Death Molecular Analysis
Gene
ABCC8
ABCC9

ACTC1
ACTN2
ACVRL1
ADAR
ADGRG1
ADGRV1
AKAP9
ALDH7A1
ALG13
ALPK3
ANK2
ANKRD1
AP3B2
ARFGEF2

ARHGEF9
ATP1A2
BAG3

Function
ATP Binding Cassette
Subfamily C Member 8
ATP-binding cassette,
sub-family C (CFTR/MRP),
member 9

Associated phenotypes
Familial Hyperinsulinism

Cantu syndrome
Dilated cardiomyopathy (DCM) Bienengraeber
et al [2004]
Atrial fibrillation (AF) Olson et al [2007]
Early repolarization syndrome (ERS)
Actin, alpha cardiac muscle 1 HCM
Alpha-actinin-2
HCM
Activin A receptor, type
Hereditary haemorrhagic
2-like 1
telangiectasia/Pulmonary arterial hypertension
Aicardi-Goutières syndrome, Dyschromatosis
symmetrica hereditaria
adhesion G protein-coupled Bilateral frontoparietal Polymicrogyria (BFPP)
receptor G1
Adhesion G protein-coupled Usher syndrome, febrile seizures?
receptor V1
A kinase (prka) anchor
LQTS type 11
protein (yotiao) 9
Aldehyde dehydrogenase 7
Epilepsy, pyridoxine-dependent
family, member a1
Lennox-Gastaut
Alpha kinase 3
Cardiomyopathy, pediatric
Ankyrin 2, neuronal
LQTS type 4
Ankyrin
HCM;DCM
repeat domain-containing
protein 1
Adaptor-related protein
Epileptic encephalopathy, early onset with optic
complex 3, beta 2 subunit
atrophy
ADP-ribosylation factor
Periventricular heterotopia with
guanine nucleotide-exchange microcephaly/west syndrome/cardiomyoapthy
factor 2 (brefeldin
A-inhibited)
Cdc42 guanine nucleotide
Epileptic encephalopathy, early infantile
exchange factor (GEF) 9
ATPase, Na+/K+
Familial basilar migraine, alternating hemiplegia
transporting, alpha 2 (+)
polypeptide
BAG family molecular
Progressive myofibrillar myopathy
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BMP2
BMPR2
BRAF
CACNA1A

CACNA1C
CACNA1E
CACNA1H
CACNA2D1

CACNA2D2
CACNB2
CALM1
CALM2
CALM3
CALR3
CASK
CASQ2
CASR

chaperone regulator 3
Bone Morphogenetic Protein
2, secreted ligand of the
TGF-beta
Bone morphogenetic protein
receptor, type II
(serine/threonine kinase)
V-raf murine sarcoma viral
oncogene homologue b1
Calcium channel, voltage
dependent, P/Q type, alpha
1A subunit (spinocerebellar
ataxia 6 SCA6)
CaV1.2 L-type calcium
channel
Calcium channel,
voltage-dependent, R type,
alpha 1E subunit
Calcium channel,
voltage-dependent, alpha 1H
subunit
Calcium channel,
voltage-dependent, alpha
2/delta subunit 1
calcium channel,
voltage-dependent, alpha
2/delta subunit 2
Calcium channel,
voltage-dependent, beta 2
subunit
Calmodulin 1 (phosphorylase
kinase, delta)
Calmodulin 2 (phosphorylase
kinase, delta)
Calmodulin 3 (phosphorylase
kinase, delta)
Calreticulin 3
Calcium/calmodulin-depende
nt serine protein kinase
(MAGUK family)
Calsequestrin 2 (cardiac
muscle)
activating mutation of
the calcium-sensing receptor

Short stature with skeletal and cardiac
anomalies/Wolff-Parkinson-White & Alagille
syndrome
Heritable Pulmonary Arterial Hypertension
Cardio-facio-cutaneous syndrome;LEOPARD;
Cardiofaciocutaneous syndrome
Migraine, familial hemiplegic, Episodic ataxia

Brugada syndrome 3; Long QT syndrome
Splawski et al [2004];Timothy syndrome
Epileptic encephalopathy with infantile spasms
Childhood absence epilepsy
Brugada
Short QT syndrome Templin et al [2011]
Early repolarization syndrome Burashnikov et al
[2010]
Schezophrenia; Epileptic encephalopathy, early
infantile
Brugada syndrome 4; Lambert-Eaton
myasthenic syndrome Taviaux et al [1997]
Long QT syndrome Burashnikov et al [2010]
LQTS type 14
LQTS type 15
long QT syndrome/CPVT
HCM
Mental retardation and microcephaly with
pontine and cerebellar hypoplasia, FG
syndrome, Mental retardation
CPVT
Bartter's syndrome associated with autosomal
dominant hypocalcemia; type 5;Hypocalcemia,
Neonatal hyperparathyroidism, Familial
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CAV3
CC2D2A
CDH2
CDKL5
CHD2
CHRNA2
CHRNA4
CHRNB2
CHRNE

CLCN2
CLCNKB
CNPY3
CNTNAP2

Caveolin 3
Coiled-coil and C2 domain
containing 2A
Cadherin 2, type 1,
N-cadherin (neuronal)
Cyclin-dependent kinase-like
5
Chromodomain helicase
DNA binding protein 2
Cholinergic receptor,
nicotinic, alpha 2 (neuronal)
Acetylcholine receptor,
neuronal nicotinic, alpha-4
subunit
Cholinergic receptor,
nicotinic, beta polypeptide 2
(neuronal)
Acetylcholine receptor,
muscle, epsilon subunit

Chloride channel 2
Cl− channel
Canopy 3 homolog
(zebrafish)
Contactin associated
protein-like 2

CPA6
CRLF1

Carboxypeptidase A6
cytokine receptor

CRYAB

Crystallin, alpha B

Hypocalciuric hypercalcemia with transient
Neonatal hyperparathyroidism
LQTS type 9
COACH syndrome, Joubert syndrome
ARVC
Epileptic encephalopathy, early infantile, Rett
syndrome, atypical, Angelman-like syndrome
Epileptic encephalopathy, childhood-onset
(Lennox-Gastaut)
Epilepsy, nocturnal frontal lobe
Epilepsy, nocturnal frontal lobe
Epilepsy, nocturnal frontal lobe
Congenital Myasthenic Syndromes:
neonatal-onset subtype include: respiratory
insufficiency with sudden apnea and cyanosis;
feeding difficulties; poor suck and cry; choking
spells; eyelid ptosis; and facial, bulbar, and
generalized weakness.
Leukoencephalopathy with ataxia, Epilepsy
classic Bartter's syndrome; type3
west syndrome
autism, Pitt-Hopkins like syndrome, Cortical
dysplasia-focal epilepsy syndrome: distinctive
facial features which become more apparent
with age (100%), developmental
delay/intellectual disability (100%), and
episodic hyperventilation and/or breath-holding
while awake (55%-60%)
Familial temporal lobe Epilepsy
Cold-Induced Sweating Syndrome Including
Crisponi Syndrome (Infants with Crisponi
syndrome require close monitoring for risk of
laryngospasm with respiratory distress and for
bouts of hyperthermia, which may lead to
seizures or sudden death
Cataract, congenital; The novel αB-crystallin
(CRYAB) mutation p.D109G causes restrictive
cardiomyopathy. Muscular dystrophy,
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CSF1R
CSRP3
CSTB
CTNNA3
DEPDC5
DES
DMD
DNM1
DOLK
DPYD
DSC2
DSG2
DSP
DTNA
DYRK1A
EEF1A2
EFHC1
EMD
EPM2A
FGFR3
FGF12
FHL1
FHL2
FHOD3
FKRP
FKTN

Cysteine and glycine-rich
protein 3
Cystatin B
Catenin (cadherin-associated
protein), alpha 3
DEP domain containing 5
Desmin
Dystrophin
Dynamin 1
Dolichol kinase
Dihydropyrimidine
dehydrogenase
Desmocollin 2
Desmoglein-2
Desmoplakin (DPI,DPII)
Dystrobrevin, alpha
Dual-specificity
tyrosine-(Y)-phosphorylation
regulated kinase 1A
Eukaryotic translation
elongation factor 1 alpha 2
EF-hand domain (C-terminal)
containing 1
Emery-Dreyfuss muscular
dystrophy (Emerin)
Epilepsy, progressive
myoclonus type 2, Lafora
disease (Laforin)
Chr4:1803571
Fibroblast growth factor 12

hypertonic fatal infantile
Leukoencephalopathy, diffuse hereditary, with
spheroids
HCM
Epilepsy, progressive myoclonic
ARVC
Epilepsy, familial focal, with variable foci
DCM, desmin related myopathy, ARVC
Dystrophinopathies (Duchenne muscular
dystrophy, Becker muscular dystrophy)
Epileptic encephalopathy
CDG with cardiomyopathy
Dihydropyrimidine dehydrogenase deficiency;
5-fluorouracil toxicity
ARVC
ARVC
ARVC
DCM/LVNC
Epilepsy with learning disorder
Epileptic encephalopathy, early infantile, Mental
retardation, dilated cardiomyopathy
Epilepsy, myoclonic juvenile, Epilepsy, severe
intractable, Epilepsy, juvenile absence
Emery-Dreifuss Muscular Dystrophy (EDMD)
Epilepsy, progressive myoclonic

Muenke Syndrome (phenotypic variability)
Epileptic encephalopathy with cerebellar
atrophy; brugada
Four and a half LIM domains Reducing body myopathy; Emery-Dreifuss
1
Muscular Dystrophy (EDMD)
Four and a half LIM domains HCM
2
Formin homology 2 domain HCM, DCM
containing 3
FKRP fukutin related protein dystroglycanopahtyies; congenital muscular
dystrophy, respiratory deficiancy
Fukutin
DCM, muscular dystrophy, respiratory
weakness, seizures
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FLNA

Filamin A, alpha
(actin-binding protein-280)

FLNC
FOLR1

filamin C, gamma
Folate receptor 1 (adult)

FOXG1

Forkhead box G1

GABRA1

Gamma-aminobutyric acid
(GABA) A receptor, alpha 1

GABRB1

Gamma-aminobutyric acid
type A receptor beta1 subunit
Gamma amino-butyric acid
(GABA) A receptor, beta 3
Gamma-aminobutyric acid
(GABA) A receptor, delta

GABRB3
GABRD
GABRG2
GAMT
GCH1

GFAP
GJA5
GLA
GLI2
GLRA1
GNAO1

GNB2
GNB5
GPD1L

Gamma-aminobutyric acid
(GABA) A receptor, gamma
2
guanidinoacetate
N-methyltransferase
GTP cyclohydrolase 1

Glial fibrillary acidic protein
gap junction protein
Galactosidase alpha
GLI - Kruppel family
member GLI2
Glycine receptor alpha 1
Guanine nucleotide binding
protein (G protein), alpha
activating activity
polypeptide O
Guanine nucleotide binding
protein (G protein), beta
polypeptide 2
Guanine nucleotide binding
protein (G protein), beta 5
Glycerol-3-phosphate

Heterotopia, periventricular, Frontometaphyseal
dysplasia, Osteodysplasty Melnick-Needles,
Otopalatodigital syndrome type 1,
Otopalatodigital syndrome type 2, Terminal
osseous dysplasia with pigmentary defects
HCM;DCM
Cerebral folate deficiency;Neurodegeneration
with brain iron accumulation
Progressive myoclonic epilepsy
Rett syndrome, epilespy congenital variant
(Lennox-Gastaut )
Epileptic encephalopathy, early infantile,
Epilepsy, childhood absence, Epilepsy, juvenile
myoclonic
Epileptic encephalopathy
Epilepsy, childhood absence (Lennox-Gastaut
Syndrome)
Epilepsy, generalized with febrile seizures plus,
Epilepsy, idiopathic generalized, Epilepsy,
juvenile myoclonic
Generalized epilepsy with febrile seizures plus,
Familial febrile seizures, Dravet syndrome,
Epilepsy, childhood absence
creatine deficiency syndromes;
Guanidinoacetate methyltransferase deficiency
Dopa-Responsive Dystonia
Hyperphenylalaninemia, BH4-deficient, GTP
Cyclohydrolase 1-Deficient Dopa-Responsive
Dystonia
Alexander disease; leukodystrophies
AF
Fabry disease
Holoprosencephaly-like phenotype;
Culler-Jones syndrome
Hereditary hyperplexia
Epileptic encephalopathy, early infantile

Sinus node dysfunction and atrioventricular
block
seizures, intellectual disorder with cardiac
arrhythmia
Brugada syndrome 2
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GRIN1
GRIN2A
GRIN2B
HCN1
HCN2
HCN4
HNRNPU
IER3IP1
JPH2
JUP
KCNA1
KCNA2
KCNA5
KCNAB2
KCNB1
KCNB2
KCNC1

dehydrogenase 1-like
Glutamate receptor,
ionotropic, N-methyl
D-aspartate 1
Glutamate receptor,
ionotrophic, N-methyl
D-aspartate 2A
Glutamate receptor,
ionotropic, N-methyl
D-aspartate 2B
Hyperpolarization activated
cyclic nucleotide-gated
potassium channel 1
Hyperpolarization activated
cyclic nucleotide-gated
potassium channel 2
Hyperpolarization activated
cyclic nucleotide-gated
potassium channel 4
Heterogeneous nuclear
ribonucleoprotein U (scaffold
attachment factor A)
Immediate early response 3
interacting protein 1
junctophilin 2
junctophilin plakoglobin
Potassium voltage-gated
channel, Shaker-related
subfamily, member 1
Potassium channel, voltage
gated shaker related
subfamily A, member 2
Potassium voltage-gated
channel, Shaker-related
subfamily, member 5

Epileptic encephalopathy, early onset with
involuntary movements, developmental delay &
intellectual disability; Mental retardation
Epilepsy, focal, with speech disorder
Epileptic encephalopathy, early infantile, Mental
retardation
Epileptic encephalopathy, early infantile
Generalized epilepsy with febrile seizures plus
(GEFS+)
Brugada syndrome; AF, sick sinus syndrome;
Intellectual disability and seizures
Microcephaly with simplified gyration, epilepsy
& diabetes;Microcephaly, epilepsy, and neonatal
diabetes
HCM
HCM, DCM; ARVC?; Naxos disease
Episodic ataxia/myokymia syndrome
Epileptic encephalopathy, early infantile
AF
Brugada, epilepsy
Early infantile epileptic encephalopathy

Potassium voltage-gated
channel, Shab-related,
member 1
Potassium voltage-gated
brugada, ataxia
channel, Shab-related
subfamily, member 2
potassium channel, voltage
Epilepsy, progressive myoclonic
gated Shaw related subfamily
C, member 1
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KCND2

Potassium voltage-gated
channel, Shal-related
subfamily, member 2

KCNE1

KCNE5

Potassium voltage gated
channel, Isk related family,
member 1
Potassium voltage gated
channel, Isk related family,
member 2
Potassium voltage-gated
channel, Isk-related family,
member 3
Potassium voltage-gated
channel, isk-related family,
member 4
AKA KCNE1L

KCNH2

HERG

KCNJ1

thick ascending limb
K+ channel;AKA ROMK1s
Potassium
inwardly-rectifying channel,
subfamily J, member 10
Potassium
inwardly-rectifying channel,
subfamily J, member 11
Potassium
inwardly-rectifying channel,
subfamily J, member 16
Potassium
inwardly-rectifying channel,
subfamily J, member 2
Potassium
inwardly-rectifying channel,
subfamily J, member 5
Potassium
inwardly-rectifying channel,
subfamily J, member 8
Potassium channel, subfamily
K, member 17
Potassium channel, subfamily

KCNE2
KCNE3
KCNE4

KCNJ10
KCNJ11
KCNJ16
KCNJ2
KCNJ5
KCNJ8
KCNK17
KCNK3

Epilepsy Singh et al [2006]
Autism with seizures Lee et al [2014]
J-wave syndromes associated w/sudden cardiac
death Perrin et al [2014]
LQTS type 5;Jervell and Lange-Nielsen
Syndrome
LQTS type 6
Brugada syndrome 6;Hyperkalemic periodic
paralysis Sternberg et al [2003]; LQT Ohno
(2009)
not established SIDS
Atrial fibrillation
idiopathic ventircular fibrillation
Long QT syndrome Curran et al [1995],
Schulze-Bahr et al [1995]
Short QT syndrome Brugada et al [2004],
Grunnet et al [2008]
Atrial fibrillation Sinner et al [2008]
neonatal Bartter's syndrome; type 2
EAST/SeSAME syndrome
Familial Hyperinsulinism
Brugada syndrome
Andersen-Tawil Syndrome;LQTS type 7
Aldosteronism, early-onset; LQTS type 13
cantu syndrome; Idiopathic ventricular
fibrillation
Arrhythmia
Pulmonary arterial hypertension
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KCNMA1
KCNQ1
KCNQ2
KCNQ3
KCNT1
KCTD7
KMT2D
LAMA4
LAMP2
LDB3
LGI1
LMNA
MAP2K1
MECP2
MYBPC3
MYBPHL
MYH6
MYH7
MYL2
MYL3
MYL4
MYLK2

K, member 3
Potassium large conductance
calcium-activated channel,
subfamily M, alpha member 1
Potassium voltage gated
channel, KQT-like subfamily,
member 1
Potassium voltage gated
channel, KQT-like subfamily,
member 2
Potassium voltage gated
channel, KQT-like subfamily,
member 3
Potassium channel, subfamily
T, member 1
Potassium channel
tetramerisation domain
containing 7
Myeloid/lymphoid or
mixed-lineage leukemia 2
laminin alpha 4
lysosomal-associated
membrane protein
LIM domain-binding protein
3
Leucine-rich, glioma
inactivated 1
Prelamin-A/C
Mitogen-activated protein
kinase kinase 1
Methyl CpG binding protein
2
Myosin-binding protein C,
cardiac type
Myosin binding protein
H-like
Myosin-6
Myosin-7
Myosin regulatory light chain
2, ventricular/cardiac muscle
isoform
Myosin light chain 3
Myosin, light chain 4, alkali;
atrial, embryonic
Myosin light chain kinase 2,

Paroxysmal nonkinesigenic dyskinesia w/or w/o
generalized epilepsy
LQTS type 1;Jervell and Lange-Nielsen
Syndrome
Epileptic encephalopathy, early infantile,
Benign familial neonatal seizures, Myokymia
Seizures, benign neonatal
Epilepsy, nocturnal frontal lobe
Epilepsy, progressive myoclonic
Kabuki syndrome
DCM; HCM
Danon; HCM
Myofibrillar myopathy; not established
Epilepsy, familial temporal lobe
Partial lipodystrophy;CMT2B1;
CMT2B1;CMT2B1;Atypical Werner syndrome
Cardio-facio-cutaneous syndrome
Angelman-like syndrome, Autism, Rett
syndrome, Encephalopathy, Mental retardation
HCM
Dilated cardiomyopathy & arrhythmias
HCM
HCM
HCM
HCM
Atrial fibrillation, early-onset
HCM
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MYOZ2
MYPN

NEBL
NEXN
NHLRC1
NKX2-5
NOS1AP
NOTCH3
NPPA
NPRL2
NSD1

PAFAH1B1
PCDH19
PDLIM3
PHOX2B
PKP2
PLCB1
PLN
PMM2
PNKP
PNPO
POLG
POLR3A
POLR3B

skeletal muscle
Myozenin-2
Myopalladin

Nebulette
Nexilin
NHL repeat containing 1;
also known as EPM2B
NK2 transcription factor
related, locus 5 (Drosophila)
(CSX)

HCM
Biallelic Mutations in MYPN, Encoding
Myopalladin, Are Associated with
Childhood-Onset, Slowly Progressive Nemaline
Myopathy. but typically not cardiac dysfunction.
dcm
Atrial septal defect, HCM;dcm
Epilepsy, progressive myoclonic
various of cardiac diseases
Long QT syndrome
Cerebral arteriopathy with subcortical infarcts
and leukoencephalopathy (CADASIL)
AF

Notch (drosophila)
homologue 3
Natriuretic peptide precursor
A
NPR2-like, GATOR1
Focal epilepsy;Temporal lobe epilepsy
complex subunit
Nuclear receptor binding SET Sotos syndrome 1 (distinctive facial appearance,
domain protein 1
overgrowth in childhood, and learning
disabilities or delayed development of mental
and movement abilities. )
Platelet activating factor
Lissencephaly
acetylhydrolase, isoform Ib,
alpha subunit (45kD)
Protocadherin 19
Epileptic encephalopathy, early infantile
PDZ and LIM domain 3
HCM/DCM
Paired-like homeobox 2b
Congenital Central Hypoventilation Syndrome
Plakophilin 2
ARVC
phospholipase C, beta 1
Epileptic encephalopathy, early infantile
(phosphoinositide-specific)
Cardiac phospholamban
ARVC, DCM, HCM
Phosphomannamutase 2
Congenital disorder of glycosylation
Polynucleotide kinase
Epileptic encephalopathy, early infantile,
3'-phosphatase
Ataxia-oculomotor apraxia 4
Pyridoxine 5'-phosphate
Pyridoxamine 5'-phosphate oxidase deficiency
oxidase
Polymerase (DNA directed), Mitochondrial DNA depletion syndrome,
gamma
progressive external opthalmoplegia
Polymerase (RNA) III (DNA Leukodystrophy, hypomyelinating
directed) polypeptide A,
155kDa
Polymerase (RNA) III (DNA Leukodystrophy, hypomyelinating
directed) polypeptide B
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PPA2
PPP3CA
PRDM16
PRICKLE1
PRKAG2
PRRT2

PTPN11

RAF1
RANGRF
RBM20
RELN
RPGRIP1L
RYR2
SCARB2
SCN10A

SCN1A
SCN1B

Protein phosphatase 3,
catalytic subunit, alpha
isozyme
PR domain containing 16
Prickle homologue 1
Protein kinase,
AMP-activated, gamma 2
non-catalytic subunit
Proline-rich transmembrane
protein 2

Cardiac arrest in infancy
Neurodevelopmental disease, severe with
seizures

cardiomyopathy/SUD
Epilepsy, progressive myoclonic
Wolff-Parkinson-White syndrome, familial
hypertrophic cardiomyopathy, and glycogen
storage disease of the heart.
Episodic kinesigenic dyskinesia;benign familial
infantile epilepsy (BFIE), paroxysmal
kinesigenic dyskinesia with infantile
convulsions (PKD/IC), and hemiplegic migraine
(HM).
Protein tyrosine phosphatase, noonan (pulmonary valve stenosis with
non-receptor tpe 11
dysplastic pulmonary valve also atrial septal
defect and hypertrophic cardiomyopathy), short
stature, learning problems, pectus excavatum,
impaired blood clotting, and a characteristic
configuration of facial features including a
webbed neck and a flat nose bridge. NS is a
RASopathy, and is one of several disorders that
are caused by a disruption of RAS-MAPK
signaling pathway.)
V-raf-1 murine leukaemia
viral oncogene homologue 1
RAN guanine nucleotide
Brugada
release factor
RNA-binding protein 20
DCM
Reelin
Lissencephaly, Epilepsy, familial temporal lobe
Rpgrip1-like
COACH syndrome; Joubert Syndrome
Ryanodine receptor 2
CPVT, ARVC
(cardiac)
Scavenger receptor class B,
Epilepsy, progressive myoclonic; Action
member 2
Myoclonus – Renal Failure Syndrome
Sodium channel,
Peripheral neuropathy Faber et al [2012]
voltage-gated, type X, alpha Atrial fibrillation Jabbari et al [2015]
subunit
Alterations of QRS duration Sotoodehnia et al
[2010]
Sodium channel,
Migraine, familial hemiplegic, Epileptic
voltage-gated, type I, alpha
encephalopathy, early infantile, Generalized
polypeptide
epilepsy with febrile seizures plus
Sodium channel,
Brugada syndrome 5; Temporal lobe epilepsy
voltage-gated, type 1, beta
Scheffer et al [2007]
polypeptide
Generalized epilepsy w/febrile seizures plus
type 1 (GEFS+1)
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SCN2A
SCN2B
SCN3B
SCN4A
SCN4B
SCN5A

SCN8A
SCN9A
SEPSECS
SGCD
SIK1
SLC12A1
SLC12A3

SLC12A5
SLC13A5
SLC25A22

SLC2A1

Sodium channel,
voltage-gated, type II, alpha
subunit
Sodium channel,
voltage-gated, type II, beta
Sodium channel,
voltage-gated, type III, beta
Sodium channel, voltage
gated, type IV, alpha
polypeptide
Sodium channel,
voltage-gated, type iv, beta
Sodium channel protein type
5 subunit alpha

Atrial fibrillation Watanabe et al [2009]
Epileptic encephalopathy, early infantile,
Seizures, benign familial infantile
AF;brugada
Brugada syndrome 7; Atrial fibrillation Wang et
al [2010]
myotonia, Essential tremor and epilepsy
susceptibility
LQTS type; AF

Brugada syndrome;LQTS type 3;Long QT
syndrome 3;Brugada syndrome
Idiopathic ventricular fibrillation
Sick sinus syndrome
Cardiac conduction system disease
Sodium channel, voltage
Cognitive impairment, Epileptic
gated, type viii, alpha
encephalopathy, early infantile
(Lennox-Gastaut )
Sodium channel,
Paroxysmal extreme pain disorder;Congenital
voltage-gated, type IX, alpha indifference to pain;Erythromelalgia, primary
Sep (O-phosphoserine)
earlier onsetEpileptic encephalopathy, early
tRNA:Sec (selenocysteine)
onset, with burst suppression; Pontocerebellar
tRNA synthase
hypoplasia, type 2D
Delta-sarcoglycan
Delta sarcoglycanopathy (LGMD2F); Muscular
dystrophy, limb girdle
Salt-inducible kinase 1
Epileptic encephalopathy, early infantile
Na-K-2Cl symporter; aka
neonatal Bartter's syndrome; type 1
NKCC2
Sodium-chloride
Gitelman's syndrome (kidney disorder that
symporter;aka NCCT
causes an imbalance of charged atoms (ions) in
the body, including ions of potassium,
magnesium, and calcium.)
Solute carrier family 12
Epileptic encephalopathy, early infantile
(potassium/chloride
transporter), member 5
Solute carrier family 13
Epileptic encephalopathy, early infantile
(sodium-dependent citrate
transporter), member 5
Solute carrier family 25
Epileptic encephalopathy, early infantile
(mitochondrial
carrier:glutamate), member
22
Solute carrier family 2
Glucose transporter 1 deficiency syndrome;
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SLC35A2
SLC4A3
SLC6A1
SLC6A8

(facilitated glucose
transporter), member 1
(GLUT1)
Solute carrier family 35
(UDP-galactose transporter),
member A2
Solute carrier family 4, anion
exchanger, member 3
Solute carrier family 6
(neurotransmitter transporter,
GABA), member 1
Solute carrier family 6
(neurotransmitter transporter,
creatine), member 8

SLMAP
SMC1A
SNTA1

SPTAN1
STX1B
STXBP1
SUOX
SURF1
SYN1
SYNGAP1
SZT2
TAZ
TBC1D24

Structural maintenance of
chromosomes 1A
Syntrophin, alpha 1
(dystrophin-associated
protein A1, 59kDa, acidic
component)
Spectrin, alpha,
non-erythrocytic 1
(alpha-fodrin)
Syntaxin 1B
Syntaxin binding protein 1

Stomatin-deficient cryohydrocytosis with
neurologic defects, Epilepsy, idiopathic
generalized, GLUT1 deficiency syndrome
Congenital disorder of glycosylation; Epileptic
encephalopathy, early onset
short QT
Epilepsy with myoclonic-atonic seizures
Creatine deficiency syndrome
not established for brugada; Muscular dystrophy
Bönnemann & Finkel [2002]
Epilepsy, early-onset, with cluster seizures;
Cornelia de Lange syndrome 2
LQTS type 12

Epileptic encephalopathy, early infantile

Generalized epilepsy with febrile seizures plus
Epileptic encephalopathy, early infantile
(Lennox-Gastaut)
Sulphite oxidase
Sulfocysteinuria (Sulphite oxidase deficiency)
Surfeit 1
Leigh syndrome
Synapsin I
Epilepsy, with variable learning disabilities and
behavior disorders
Synaptic Ras GTPase
Intellectual disability with epilepsy; Mental
activating protein 1 homolog retardation
(rat)
Seizure threshold 2
Epileptic encephalopathy, early infantile
homologue (mouse)
Tafazzin
Barth Syndrome;Endocardial fibroelastosis type
2;Familial isolated non-compaction of the left
ventricular myocardium
TBC1 domain family,
Deafness, Deafness, onychodystrophy,
member 24
osteodystrophy, mental retardation, and seizures
(DOORS) syndrome;Familial infantile
myoclonic epilepsy (FIME). Early-onset
myoclonic seizures, focal epilepsy, dysarthria,
and mild-to-moderate intellectual
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TBCD
TBX5
TCAP
TCF4

Tubulin folding cofactor D

TECRL

Trans-2,3-enoyl-CoA
reductase-like
tight junction protein 1
Transmembrane protein 43
Transmembrane protein 67

TJP1
TMEM43
TMEM67
TMPO
TNNC1
TNNI3
TNNI3K
TNNT2
TPM1
TPP1
TRDN
TRPM4
TSC1
TSC2
TTN
TTR
TUBA1A

Telethonin
Transcription factor 4

disability;Progressive myoclonus epilepsy
(PME). Action myoclonus, tonic-clonic seizures,
progressive neurologic decline, and ataxia
Early-infantile epileptic encephalopathy 16
(EIEE16). Epileptiform EEG abnormalities
which themselves are believed to contribute to
progressive disturbance in cerebral function
Autosomal recessive nonsyndromic hearing loss,
DFNB86. Profound prelingual deafness
Autosomal dominant nonsyndromic hearing
loss, DFNA65. Slowly progressive deafness
with onset in the third decade, initially affecting
the high frequencies
Encephalopathy, early-onset
Holt-Oram syndrome
HCM
Pitt-Hopkins syndrome; Corneal dystrophy,
Fuchs endothelial,
Cardiac arrhythmia
ARVC
ARVC
COACH syndrome; Joubert Syndrome (brain
abnormalities that together are known as the
molar tooth sign)

Lamina-associated
polypeptide 2, isoform alpha
Troponin C, slow skeletal and HCM, DCM
cardiac muscles
Troponin I, cardiac muscle
HCM, DCM
Conduction system disease, atrial
tachyarrhythmia & dilated cardiomyopathy
Troponin T, cardiac muscle
HCM, DCM
Tropomyosin alpha-1 chain
HCM, DCM
Tripeptidyl peptidase I
Spinocerebellar ataxia, Neuronal ceroid
(CLN2)
lipofuscinosis type 2
Triadin
CPVT
Transient receptor potential
Progressive familial heart block type 1B Kruse
cation channel, subfamily M, et al [2009]
member 4
Tuberous sclerosis 1
Tuberous sclerosis;Lymphangioleiomyomatosis,
Tuberous sclerosis
Tuberous sclerosis 2
Tuberous sclerosis
Titin
ARVC
Transthyretin (prealbumin)
Amyloidosis
Tubulin
Lissencephaly 3; Tubulinopathies
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TUBB2A
TUBB2B
TUBB3
TUBB4A
VCL
VPS13A
XIRP2

Tubulin

Cortical dysplasia, complex with other brain
malformations 5; Epilepsy, infantile-onset &
abnormal brain morphology
Tubulin
Cortical dysplasia, complex, with other brain
malformations 7
Tubulin, beta 3
Congenital fibrosis of the extraocular muscles 3;
Cortical development malformations and
neuronal migration defects
Tubulin
Leukodystrophy, hypomyelinating,
Dystonia;Tubulinopathies
Vinculin
DCM; HCM
Vacuolar protein sorting 13A Choreoacanthocytosis
(yeast), CHAC
SUD

